Works by Shoaf, Susan E.
Results: 23
Population-based meta-analysis of furosemide pharmacokinetics.
- Published in:
- Biopharmaceutics & Drug Disposition, 2014, v. 35, n. 2, p. 119, doi. 10.1002/bdd.1874
- By:
- Publication type:
- Article
Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
- Published in:
- Biopharmaceutics & Drug Disposition, 2013, v. 34, n. 6, p. 336, doi. 10.1002/bdd.1849
- By:
- Publication type:
- Article
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
- Published in:
- Biopharmaceutics & Drug Disposition, 2013, v. 34, n. 9, p. 527, doi. 10.1002/bdd.1863
- By:
- Publication type:
- Article
Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Effects of Hepatic or Renal Impairment on Pharmacokinetics of Aripiprazole.
- Published in:
- Clinical Pharmacokinetics, 2008, v. 47, n. 8, p. 533, doi. 10.2165/00003088-200847080-00003
- By:
- Publication type:
- Article
Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.
- Published in:
- Journal of Psychopharmacology, 2023, v. 37, n. 2, p. 164, doi. 10.1177/02698811221140008
- By:
- Publication type:
- Article
Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.
- Published in:
- Toxicological Sciences, 2017, v. 155, n. 1, p. 61, doi. 10.1093/toxsci/kfw193
- By:
- Publication type:
- Article
Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.
- Published in:
- Journal of Pharmacy & Pharmacology, 2006, v. 58, n. 1, p. 51
- By:
- Publication type:
- Article
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2012, v. 73, n. 4, p. 579, doi. 10.1111/j.1365-2125.2011.04114.x
- By:
- Publication type:
- Article
Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 5, p. 763, doi. 10.1002/jcph.1370
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 7, p. 906, doi. 10.1002/jcph.880
- By:
- Publication type:
- Article
In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 5, p. 761, doi. 10.1177/0091270010376193
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2007, v. 47, n. 12, p. 1498, doi. 10.1177/0091270007307877
- By:
- Publication type:
- Article
Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 4, p. 1535, doi. 10.1111/cts.13017
- By:
- Publication type:
- Article
Does Labeled α-Methyl-L-Tryptophan Image ONLY Blood-Brain Barrier Transport of Tryptophan? (Reply).
- Published in:
- Journal of Cerebral Blood Flow & Metabolism, 2000, v. 20, n. 10, p. 1511, doi. 10.1097/00004647-200010000-00014
- By:
- Publication type:
- Article
A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Serotonergic influences on life-history outcomes in free-ranging male rhesus macaques.
- Published in:
- American Journal of Primatology, 2007, v. 69, n. 8, p. 851, doi. 10.1002/ajp.20369
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
- Published in:
- Kidney International, 2014, v. 85, n. 4, p. 953, doi. 10.1038/ki.2013.350
- By:
- Publication type:
- Article
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
- Published in:
- Kidney International, 2013, v. 84, n. 6, p. 1278, doi. 10.1038/ki.2013.285
- By:
- Publication type:
- Article
Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2012, v. 50, n. 2, p. 150, doi. 10.5414/CP201621
- By:
- Publication type:
- Article
At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 11, doi. 10.1002/cpdd.1495
- By:
- Publication type:
- Article
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article